CIK 0001817713
- Large accelerated filer
Janux Therapeutics, Inc.
Sign in to watch- Ticker
- JANX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 822289112
- Phone
- +1 858-751-4493
- Business address
- 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 38 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-02 | Go William Chief Medical Officer | Grant or award · Stock option (right to buy) | +154,000 | 154,000 | ||
| 2026-01-02 | Doyle Janeen Noel Chief Corp. & Bus. Dev. Ofcr | Grant or award | +36,000 | 80,000 | ||
| 2026-01-02 | Doyle Janeen Noel Chief Corp. & Bus. Dev. Ofcr | Grant or award · Stock option (right to buy) | +126,000 | 126,000 | ||
| 2026-01-02 | McIver Zachariah Chief Medical Officer | Sale | −2,714 | $13.73 | $37K | 23,286 |
| 2026-01-02 | McIver Zachariah Chief Medical Officer | Grant or award | +29,000 | 52,286 | ||
| 2026-01-02 | McIver Zachariah Chief Medical Officer | Grant or award · Stock option (right to buy) | +101,500 | 101,500 | ||
| 2026-01-02 | Dobek Maria Vice President, Accounting | Sale | −1,462 | $13.73 | $20K | 15,373 |
| 2026-01-02 | Dobek Maria Vice President, Accounting | Grant or award | +18,935 | 34,308 | ||
| 2026-01-02 | Dobek Maria Vice President, Accounting | Grant or award · Stock option (right to buy) | +42,600 | 42,600 | ||
| 2026-01-02 | DiRaimondo Thomas Chief Scientific Officer | Sale | −2,505 | $13.73 | $34K | 124,425 |
| 2026-01-02 | DiRaimondo Thomas Chief Scientific Officer | Grant or award | +31,400 | 155,825 | ||
| 2026-01-02 | DiRaimondo Thomas Chief Scientific Officer | Grant or award · Stock option (right to buy) | +109,900 | 109,900 | ||
| 2026-01-02 | Winter Charles M. Chief Technical Officer | Sale | −2,401 | $13.73 | $33K | 77,721 |
| 2026-01-02 | Winter Charles M. Chief Technical Officer | Grant or award | +28,600 | 106,321 | ||
| 2026-01-02 | Winter Charles M. Chief Technical Officer | Grant or award · Stock option (right to buy) | +100,100 | 100,100 | ||
| 2026-01-02 | Meyer Andrew Hollman Chief Business Officer | Sale | −1,879 | $13.73 | $26K | 83,095 |
| 2026-01-02 | Campbell David Alan President and CEO | Sale | −8,072 | $13.73 | $111K | 284,982 |
| 2026-01-02 | Campbell David Alan President and CEO | Grant or award | +96,600 | 381,582 | ||
| 2026-01-02 | Campbell David Alan President and CEO | Grant or award · Stock option (right to buy) | +338,100 | 338,100 | ||
| 2025-12-01 | Meyer Andrew Hollman Chief Business Officer | Option exercise 10b5-1 | +3,333 | $10.59 | $35K | 88,307 |
Page 2 of 15 · 294 trades